Table 1.
Key results from 2009 ACTwatch survey in Kinshasa
| Dates of data collection | August–September 2009 |
| Sample | N |
| Outlets screened | 2368 |
| Outlets interviewed | 778 |
| Among all screened outlets, percentage that had | % (95% CI) |
| Public sector availability of quality-assured ACT | 48.5 (32.8, 64.6) |
| Private sector availability of quality-assured ACT | 14.1 (10.6, 18.6) |
| Public sector availability of non quality-assured ACT | 20.0 (11.4, 32.8) |
| Private sector availability of non quality-assured ACT | 60.7 (55.2, 66.0) |
| Public sector availability of oral artemisinin monotherapy | 26.0 (15.4, 40.3) |
| Private sector availability of oral artemisinin monotherapy | 70.4 (65.4, 75.0) |
| Anti-malarial market share | % |
| Market share of oral artemisinin monotherapy | 10.8 |